Verrica Pharmaceuticals

$13.36 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.

Stock Analysis

last close $13.36
1-mo return 13.4%
3-mo return 29.1%
avg daily vol. 189.54T
52-week high 18.42
52-week low 7.05
market cap. $341M
forward pe -
annual div. -
roe -71.9%
ltg forecast -
dividend yield -
annual rev. $12M
inst own. 36.3%
baraka

Subscribe now for daily local and international financial news

Subscribe